Robert Förster: Phase 3 study in Prostate Cancer (Post Prostatectomy), Prostate Cancer (206 participants)
Robert Förster: Phase 3 study in Prostate Cancer (Post Prostatectomy), Prostate Cancer (206 participants). Its enrollment of 206 is above the median of 80 (77th percentile). Dated 44 days ago, it serves as a historical benchmark. Score 55/100. As of 2026-11-04, from ClinicalTrials.gov (U.S. National Library of Medicine) API v2.
Data as of · Compiled by Zalwin from ClinicalTrials.gov (U.S. National Library of Medicine) API v2
enrollment: 206 · 77th percentile of 8,879 ClinicalTrialStartPulse records · 2.6x the median
Free preview: all 13 published fields of this record are shown below. Locked: 499 related ClinicalTrialStartPulse records and the 7-column CSV export.
| Field | Value |
|---|---|
| Sponsor | Robert Förster |
| Sponsor type | Academic and hospital |
| Study | RIsk aDapted Stereotactic Radiotherapy vs. standarD of Care Radiotherapy in Patients With Prostate Cancer in the Adjuvant or saLvage sEtting With or Without Lymph Node Irradiation (RIDDLELN) - A Phase III Trial |
| NCT ID | NCT07830511 |
| Phase | Phase 3 |
| Status | not yet recruiting |
| Conditions | Prostate Cancer (Post Prostatectomy); Prostate Cancer; SBRT |
| Intervention types | radiation |
| Target enrollment | 206 |
| Posted | 2026-09-21 |
| Planned start | 2026-09-01 |
| Event | Newly registered study |
| Event date | 2026-09-21 |
| enrollment percentile | 77th of 8,879 (median 80, 2.6x median) |
| Peer records CSV (500 records) | 🔒 Click to unlock → |
| CRM-ready export with official source URLs | 🔒 Click to unlock → |
Watch Robert Förster
Free email alert. Alert me when this company gets a new filing, lien, permit, contract or expiry in this feed. One confirmation email; unsubscribe any time.
Free for 1 company. More companies from $9/mo (25), $49/mo (500 + CSV), $199/mo (500 + CSV + API). Cancel any time from the link in every email.
Unlock Robert Förster + 500 peer records (CSV)
Instant CSV download · Card, Apple Pay, Google Pay or Link via Stripe · No account required
CSV columns: Sponsor · Phase · Conditions · Enrollment · Countries · Event · Posted · official source URL
- Source agency: ClinicalTrials.gov (U.S. National Library of Medicine) API v2
- Record date: 2026-09-21
- Data refreshed: 2026-11-04
- Refunds on request within 14 days
Top ClinicalTrialStartPulse records (NONUS first): University of Oxford · DejthidaNathaphong · Eye & ENT Hospital of Fudan University · Shanghai First Maternal and Infant Health Hospital affiliate · Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Browse all by state and category →
LIVE PUBLIC DATA Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 · Last refreshed: Wed, 04 Nov 2026 06:04:38 GMT
Is this your business? Add a "Listed on Zalwin" badge to your site
Paste this snippet into your website. It links to this public record; nothing is tracked on your site.
Peer benchmark and outreach value: Robert Förster and 6,603 NONUS peers
- NONUS ClinicalTrialStartPulse records like this one: 6,603
- Robert Förster's enrollment: 77th percentile of 8,879 records
- Timing: Low: older than 30 days
- Estimated pipeline if you contact every NONUS peer: $1,320,600 (peers × rate × deal size; an estimate from your assumptions, not a forecast)
55 / 100 Score
- Phase 3: multi-site, larger budget.
- 206 participants planned.
- Not yet recruiting: vendors still being chosen.
What is the ClinicalTrialStartPulse record for Robert Förster?
Robert Förster registered a Phase 3 study (NCT07830511) in Prostate Cancer (Post Prostatectomy) targeting 206 participants, posted 2026-09-21.
How does Robert Förster compare to other ClinicalTrialStartPulse records?
Its enrollment of 206 sits in the upper half (77th percentile) of 8,879 records; the median is 80. It is 44 days old, still within a typical 45-day follow-up window.
Robert Förster vs. top 3 peers
| Organization | Location | Amount | Percentile | Record date |
|---|---|---|---|---|
| Robert Förster | NONUS | 206 | 77th | 2026-09-21 |
| Genmab | US | 191 | 75th | 2026-11-03 |
| AstraZeneca | US | 181 | 74th | 2026-11-03 |
| Janssen Research & Development, LLC | US | 159 | 72nd | 2026-11-03 |
Related records
ClinicalTrialStartPulse: Phase 3 ClinicalTrialStartPulse: Outside the US only
How to monitor Robert Förster and peer phase 3 records
Get new ClinicalTrialStartPulse records like Robert Förster by email (free, weekly)
We email one confirmation link now; the weekly digest starts only after you confirm. One-click unsubscribe in every email.
Double opt-in: nothing is sent until you click the confirmation link. One-click unsubscribe.
Get new studies in your therapeutic areas
ClinicalTrialStartPulse emails new studies and status changes matching your events, phases, sponsor types and site regions.
✓ Read-only, live public data · Key and unlock right after payment · Card, Apple Pay, Google Pay or Link via Stripe · Refunds on request within 14 days
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.